Scinai Immunotherapeutics Ltd. is a biopharmaceutical company focused on developing innovative immunology and inflammation therapies while offering specialised CDMO services through its Scinai Bioservices division.

Scinai Immunotherapeutics Ltd., formerly known as BiondVax Pharmaceuticals, is a biotechnology company headquartered in Jerusalem, Israel, and listed on Nasdaq under the ticker SCNI. The company operates at the forefront of developing innovative biological products targeting inflammation and immunology (I&I) conditions, leveraging cutting-edge technologies to advance therapeutic options.

Alongside its core research and development efforts, Scinai also provides Contract Development and Manufacturing Organisation (CDMO) services through its dedicated business unit, Scinai Bioservices. With a 1,850-square-metre facility featuring state-of-the-art clean rooms and laboratories, Scinai is equipped to handle projects in compliance with EMA and FDA cGMP standards. The company’s dual focus on proprietary product development and CDMO services positions it as a versatile partner for both early-stage biotech innovators and established pharmaceutical companies.

Key Products and Services

• Immunology and Inflammation Therapies
  • Development of proprietary biological products targeting key I&I conditions.
• CDMO Services (Scinai Bioservices)
  • Upstream and downstream process development.
  • Scale-up and analytical methods development.
  • Drug manufacturing for pre-clinical and clinical supplies.
  • Liposomal encapsulated drug development (in partnership with Ayana Pharma).

Scinai Immunotherapeutics is committed to advancing healthcare through its dual expertise in developing cutting-edge biologics and delivering high-quality CDMO solutions. With a strategic focus on innovation, compliance, and client success, Scinai is poised to strengthen its position as a trusted partner in the biopharmaceutical sector.